Everest Medicines announces board leadership changes, names honorary chairman

Everest Medicines Limited has announced a series of key leadership changes set to take effect on October 10, 2025. Wei Fu will be re-designated as a non-executive director, stepping down from his roles as chairman of the board, chairman of the nomination committee, and a member of the remuneration committee. In recognition of his contributions, Fu will be appointed as the honorary chairman of the board, a role for which he will not receive remuneration.

Concurrently, Yifang Wu will join the company as an executive director and will assume the positions of chairman of the board, chairman of the nomination committee, and a member of the remuneration committee. Wu brings over 35 years of biopharmaceutical industry experience, including previous roles at Fosun Pharma Group and as an executive operating partner of CBC Group. He will serve a three-year term, subject to re-election.

Additionally, Honggang Feng has resigned as a non-executive director, effective October 10, 2025, to focus on other business endeavors. The board expressed gratitude to both Fu and Feng for their service and welcomed Wu to his new roles.